Free Trial
NASDAQ:BCYC

Bicycle Therapeutics (BCYC) Stock Price, News & Analysis

Bicycle Therapeutics logo
$8.90 +0.34 (+3.96%)
As of 02:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Bicycle Therapeutics Stock (NASDAQ:BCYC)

Key Stats

Today's Range
$8.62
$9.09
50-Day Range
$6.38
$11.32
52-Week Range
$6.10
$28.67
Volume
135,898 shs
Average Volume
396,627 shs
Market Capitalization
$615.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.14
Consensus Rating
Moderate Buy

Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

BCYC MarketRank™: 

Bicycle Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 686th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bicycle Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Bicycle Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.06) to ($3.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bicycle Therapeutics is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bicycle Therapeutics is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bicycle Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Bicycle Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.95% of the float of Bicycle Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicycle Therapeutics has a short interest ratio ("days to cover") of 9.
  • Change versus previous month

    Short interest in Bicycle Therapeutics has recently decreased by 27.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bicycle Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicycle Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.95% of the float of Bicycle Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicycle Therapeutics has a short interest ratio ("days to cover") of 9.
  • Change versus previous month

    Short interest in Bicycle Therapeutics has recently decreased by 27.21%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Bicycle Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Bicycle Therapeutics this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,710.00 in company stock.

  • Percentage Held by Insiders

    Only 8.50% of the stock of Bicycle Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bicycle Therapeutics' insider trading history.
Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Stock News Headlines

The collapse has already started
The headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.
See More Headlines

BCYC Stock Analysis - Frequently Asked Questions

Bicycle Therapeutics' stock was trading at $14.00 at the beginning of the year. Since then, BCYC shares have decreased by 36.0% and is now trading at $8.9650.
View the best growth stocks for 2025 here
.

Bicycle Therapeutics plc (NASDAQ:BCYC) announced its earnings results on Thursday, May, 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.02. Bicycle Therapeutics had a negative net margin of 450.64% and a negative trailing twelve-month return on equity of 27.35%.

Bicycle Therapeutics (BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Top institutional investors of Bicycle Therapeutics include Principal Financial Group Inc. (0.91%), Harbor Capital Advisors Inc. (0.21%), Cerity Partners LLC (0.02%) and Exchange Traded Concepts LLC (0.02%). Insiders that own company stock include Bros Advisors Lp Baker, Kevin Lee, Michael Skynner, Alistair Milnes, Santiago Arroyo, Nicholas Keen, Michael Charles Ferguso Hannay, Nigel Crockett, Travis Alvin Thompson and Lee Kalowski.
View institutional ownership trends
.

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Grayscale Ethereum Trust (ETH) (ETHE), Curaleaf (CURLF) and Marathon Oil (MRO).

Company Calendar

Last Earnings
2/25/2025
Today
5/01/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCYC
Fax
N/A
Employees
240
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.14
High Stock Price Target
$48.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+240.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-180,660,000.00
Net Margins
-450.64%
Pretax Margin
-459.75%

Debt

Sales & Book Value

Annual Sales
$35.28 million
Price / Cash Flow
N/A
Book Value
$12.35 per share
Price / Book
0.69

Miscellaneous

Free Float
63,177,000
Market Cap
$592.37 million
Optionable
Optionable
Beta
1.40
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:BCYC) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners